FDA Policy For Device Modifications Faces Mounting Scrutiny
This article was originally published in The Gray Sheet
Legislators looking for weak spots in FDA's device pre-market review program have honed in on a perceived loophole that allows firms to change existing 510(k) products without notifying FDA
You may also be interested in...
After years of controversy, US FDA finally succeeded in updating its 20-year-old guideline on when a new 510(k) is needed for device modifications. Split out as its own document is a guideline targeting the issue specifically for software modifications.
In the EU, when do manufacturers need to tell notified bodies about an extension to their product line before placing the updated devices on the market? Is there a definitive answer, or is more clarity needed? Experts weigh in.
US FDA wants sponsors to complete risk-based assessments and thoroughly consider unintended outcomes of changes they make to already-cleared devices, says a new, highly anticipated draft guidance on 510(k) modifications. This is true whether alterations are made by manufacturers to improve safety or effectiveness, enhance labels, change technology or engineering, or to upgrade materials in a device.